(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.There was no reported device malfunction and the product was not returned as the scaffold remains in the anatomy.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effects of angina and ischemia as listed in the bioresorbable vascular scaffold (bvs) system, absorb, instructions for use (ifu) are known adverse events associated with the use of a coronary scaffold in native coronary arteries.A conclusive cause for the reported patient effects and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to the design, manufacture, or labeling of the device.The absorb device is currently not commercially available in the u.S; however, it is similar to a device sold in the us.
|
It was reported that on (b)(6) 2015 and following pre-dilatation, a 2.5x18mm absorb bioresorbable vascular scaffold (bvs) was implanted in the right posterior descending coronary artery lesion.On (b)(6) 2016, the patient was admitted to the hospital with chest discomfort, experienced for several weeks, relieved for a few minutes by nitroglycerine.Troponin was negative and there were no reported positive results.The patient was referred for a stress cardiac mri and clinic follow-up.On (b)(6) 2018, the patient was hospitalized again for exertional chest pain, relieved at rest, with reduced exercise tolerance.An electrocardiogram was performed displaying sinus rhythm.Serial troponin was negative.Angina was diagnosed in the background of ischemic heart disease.The patient was started on isosorbide mononitrate (ismn) with outpatient follow-up scheduled.The study physician indicated the device relationship to the angina is unknown.No additional information was provided.
|